MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.7 EUR | 0.00% |
|
+0.82% | +99.12% |
| Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
| Apr. 11 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
| Sales 2024 * | 252M 268M | Sales 2025 * | 325M 347M | Capitalization | 2.55B 2.72B |
|---|---|---|---|---|---|
| Net income 2024 * | -182M -194M | Net income 2025 * | -115M -123M | EV / Sales 2024 * | 9.72 x |
| Net cash position 2024 * | 106M 113M | Net cash position 2025 * | 241M 257M | EV / Sales 2025 * | 7.11 x |
| P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-32.8
x | Employees | 524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More recommendations
More press releases
More news
| 1 week | +0.97% | ||
| Current month | +0.74% | ||
| 1 month | +1.96% | ||
| 3 months | +78.16% | ||
| 6 months | +172.33% | ||
| Current year | +99.12% |
1 week
67.10
68.00
1 month
65.8268.00
Current year
29.7368.00
1 year
14.5268.00
3 years
11.8180.14
5 years
11.81146.30
10 years
11.81146.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
| Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.44% | 125 M€ | -.--% | ||
| 0.80% | 17 M€ | -.--% | - | |
| 0.11% | 2 M€ | -.--% | ||
| 0.02% | 773 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 67.7 | 0.00% | 122,121 |
| 24-04-16 | 67.7 | -0.37% | 1,405,984 |
| 24-04-15 | 67.95 | 0.00% | 1,728,595 |
| 24-04-12 | 67.95 | +0.52% | 2,164,879 |
| 24-04-11 | 67.6 | +0.67% | 286,198 |
Delayed Quote Xetra, April 17, 2024 at 11:41 am EDT
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
2024-04-28
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
67.7
EUR
Average target price
58.71
EUR
Spread / Average Target
-13.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +99.12% | 2.71B | |
| -1.78% | 41.71B | |
| +47.70% | 41.56B | |
| +4.01% | 39.74B | |
| -15.14% | 25.61B | |
| +3.16% | 24.26B | |
| -24.08% | 18.55B | |
| -2.67% | 11.93B | |
| +24.76% | 11.93B | |
| +7.01% | 10.91B |
- Stock Market
- Equities
- MOR Stock
